Related Experiment Videos
[Calciotropic hormones in rheumatology]
C Cormier1, J C Souberbielle, C Kindermans
1Service de rhumatologie, hôpital Cochin, Paris.
Annales De Biologie Clinique
|July 1, 1997
Summary
Measuring calciotropic hormones can reveal secondary osteoporosis causes, even with normal calcium levels. Early diagnosis of these hormonal imbalances is crucial for effective osteoporosis treatment.
Area of Science:
- Endocrinology
- Bone Metabolism
- Calcium Homeostasis
Context:
- Bone health is regulated by calciotropic hormones, including parathyroid hormone (PTH) and calcitriol.
- These hormones target bone tissue, and imbalances can lead to bone density loss and osteoporosis.
- Serum calcium and phosphate levels are primary indicators of hormonal anomalies.
Purpose:
- To evaluate the utility of measuring calciotropic hormones in patients with osteoporosis, particularly when bone density is unexpectedly low.
- To identify potential secondary causes of osteoporosis that may impact treatment efficacy.
- To clarify the role of calciotropic hormone measurement in managing osteopenia and osteoporosis.
Summary:
- Calciotropic hormones (PTH and calcitriol) are key regulators of calcium homeostasis and bone health.
- Elevated levels of these hormones can negatively impact bone, contributing to osteoporosis.
- Measuring calciotropic hormones is recommended when osteopenia is disproportionate to known risk factors, even with normal calcium/phosphate levels.
- This assessment can uncover secondary osteoporosis causes that may hinder the effectiveness of treatments like hormone replacement therapy and bisphosphonates.
Impact:
- Facilitates the diagnosis of previously unidentified secondary osteoporosis.
- Enables targeted treatment strategies for hormonal imbalances affecting bone density.
- May improve the effectiveness of established osteoporosis therapies by addressing underlying causes.
- Informs clinical decision-making regarding the measurement of calciotropic hormones in specific patient populations.